dc.contributor.author | Antolin, AA | |
dc.contributor.author | Workman, P | |
dc.contributor.author | Al-Lazikani, B | |
dc.date.accessioned | 2020-06-03T08:44:54Z | |
dc.date.issued | 2019-11-28 | |
dc.identifier.citation | Future medicinal chemistry, 2019 | |
dc.identifier.issn | 1756-8919 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3672 | |
dc.identifier.eissn | 1756-8927 | |
dc.identifier.doi | 10.4155/fmc-2019-0231 | |
dc.description.abstract | High-quality small molecule chemical probes are extremely valuable for biological research and target validation. However, frequent use of flawed small-molecule inhibitors produces misleading results and diminishes the robustness of biomedical research. Several public resources are available to facilitate assessment and selection of better chemical probes for specific protein targets. Here, we review chemical probe resources, discuss their current strengths and limitations, and make recommendations for further improvements. Expert review resources provide in-depth analysis but currently cover only a limited portion of the liganded proteome. Computational resources encompass more proteins and are regularly updated, but have limitations in data availability and curation. We show how biomedical scientists may use these resources to choose the best available chemical probes for their research. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Future Science Ltd | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Public resources for chemical probes: the journey so far and the road ahead. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-09-30 | |
rioxxterms.versionofrecord | 10.4155/fmc-2019-0231 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-11-28 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future medicinal chemistry | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Computational Biology and Chemogenomics | |
dc.contributor.icrauthor | Workman, Paul | |
dc.contributor.icrauthor | Al-Lazikani, Bissan | |